Drug Profile
Glecaprevir/pibrentasvir - AbbVie
Alternative Names: 2DAA; ABT-493/ABT-530; GLE/PIB; Glecaprevir Hydrate/Pibrentasvir - AbbVie; HCV Next Gen; MAVIRET; MAVYRET; Pibrentasvir/glecaprevir; Pibrentasvir/glecaprevir-AbbvieLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AbbVie; Enanta Pharmaceuticals
- Developer AbbVie
- Class Antivirals; Aza compounds; Benzimidazoles; Carbamates; Cyclic ethers; Cyclopentanes; Cyclopropanes; Fluorobenzenes; Piperidines; Pyrrolidines; Quinoxalines; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis C
Most Recent Events
- 22 Aug 2023 AbbVie in collaboration with National Institute of Allergy and Infectious Diseases (NIAID) completes a phase II PURGE-C trial for Hepatitis C in USA, Puerto Rico and Brazil (NCT04042740)
- 05 Oct 2022 Launched for Hepatitis C (Treatment-naive, Treatment-experienced) in Canada (PO)
- 15 Sep 2022 AbbVie completes a Phase-II/III clinical trial in Hepatitis C (In adolescents, In children) in Spain, USA, United Kingdom, Russia, Japan, Germany, Canada, Belgium (PO, Tablet) (NCT03067129) (EudraCT2016-004102-34)